PAA
TNYA icon

Peregrine Asset Advisers’s Tenaya Therapeutics TNYA Stock Holding History

Peregrine Asset Advisers’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,370
Closed -$20K – 194
2025
Q3 		$20K Buy
+12,370
New +$12.5K 0.01% 177

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Peregrine Asset Advisers's TNYA Position: Q4 2025 in Review

Peregrine Asset Advisers sold out of Tenaya Therapeutics (TNYA) in Q4 2025, closing a stake of 12,370 shares — an estimated $20K sold.

Peregrine Asset Advisers first reported a position in TNYA in Q3 2025 and held it in 1 quarter. The position peaked at $20K in Q3 2025. 97 funds tracked by Wall St. Rank hold TNYA as of Q4 2025.

  • Peregrine Asset Advisers reported no remaining Tenaya Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Peregrine Asset Advisers sold 12,370 Tenaya Therapeutics shares in Q4 2025, an estimated $20K.
  • Peregrine Asset Advisers first reported a position in Tenaya Therapeutics in Q3 2025 and held it in 1 quarter.
  • Peregrine Asset Advisers's Tenaya Therapeutics position peaked at $20K in Q3 2025.
  • 97 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2025.

Based on Peregrine Asset Advisers's 13F filing for Q4 2025, filed 2 Feb 2026.